205 related articles for article (PubMed ID: 18756832)
1. [Application of activated recombinant factor VII (rFVIIa, NovoSeven) in neonatology].
Georgieva R
Akush Ginekol (Sofiia); 2008; 47(3):46-50. PubMed ID: 18756832
[TBL] [Abstract][Full Text] [Related]
2. Controlled off-label use of recombinant activated factor VII (NovoSeven) can build evidence base.
Cardiovasc J Afr; 2008; 19(1):52-4. PubMed ID: 18320092
[No Abstract] [Full Text] [Related]
3. [Using recombinant activated blood coagulation factor VII for treatment of hemorrhagic syndrome in patients with thrombocytopenia].
Galstian GM; Kolosova IV
Anesteziol Reanimatol; 2014; 59(6):60-6. PubMed ID: 25831706
[TBL] [Abstract][Full Text] [Related]
4. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
[TBL] [Abstract][Full Text] [Related]
5. Is the use of rFVIIa safe and effective in bleeding neonates? A retrospective series of 8 cases.
Mitsiakos G; Papaioannou G; Giougi E; Karagianni P; Garipidou V; Nikolaidis N
J Pediatr Hematol Oncol; 2007 Mar; 29(3):145-50. PubMed ID: 17356391
[TBL] [Abstract][Full Text] [Related]
6. Traumatic bleeding at birth treated with Factor VII.
Carmo KA; O'Brien K; Teo J; Schell D
J Paediatr Child Health; 2009; 45(1-2):68-70. PubMed ID: 19208070
[TBL] [Abstract][Full Text] [Related]
7. A comparison between recombinant activated factor VII (Aryoseven) and Novoseven in patients with congenital factor VII deficiency.
Faranoush M; Abolghasemi H; Toogeh G; Karimi M; Eshghi P; Managhchi M; Hoorfar H; Dehdezi BK; Mehrvar A; Khoeiny B; Kamyar K; Heshmat R; Baghaeipour MR; Mirbehbahani NB; Fayazfar R; Ahmadinejad M; Naderi M
Clin Appl Thromb Hemost; 2015 Nov; 21(8):724-8. PubMed ID: 24651301
[TBL] [Abstract][Full Text] [Related]
8. Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage.
Brady KM; Easley RB; Tobias JD
Paediatr Anaesth; 2006 Oct; 16(10):1042-6. PubMed ID: 16972833
[TBL] [Abstract][Full Text] [Related]
9. [Using recombinant activated coagulation factor VII (NovoSeven) in obstetrics].
Pekhlivanov B; Milchev N; Abrashev B
Akush Ginekol (Sofiia); 2003; 42(6):7-9. PubMed ID: 15067806
[TBL] [Abstract][Full Text] [Related]
10. Applicability and safety of recombinant activated factor VII to control non-haemophilic haemorrhage: investigational experience in 265 children.
Herbertson M; Kenet G
Haemophilia; 2008 Jul; 14(4):753-62. PubMed ID: 18445016
[TBL] [Abstract][Full Text] [Related]
11. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease.
Razon Y; Erez E; Vidne B; Birk E; Katz J; Tamari H; Dagan O
Paediatr Anaesth; 2005 Mar; 15(3):235-40. PubMed ID: 15725322
[TBL] [Abstract][Full Text] [Related]
12. Change of coagulation after NovoSeven® use for bleeding during cardiac surgery.
Tomita E; Takase H; Tajima K; Suematsu Y
Asian Cardiovasc Thorac Ann; 2017 Feb; 25(2):99-104. PubMed ID: 28114794
[TBL] [Abstract][Full Text] [Related]
13. The use of recombinant activated factor VII in trauma patients: Experience from the Australian and New Zealand haemostasis registry.
Cameron P; Phillips L; Balogh Z; Joseph A; Pearce A; Parr M; Jankelowitz G
Injury; 2007 Sep; 38(9):1030-8. PubMed ID: 17706654
[TBL] [Abstract][Full Text] [Related]
14. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
[TBL] [Abstract][Full Text] [Related]
15. Effect of recombinant activated factor VII in critical bleeding: clinical experience of a single center.
Sartori MT; Imbergamo S; Zanon E; Bonaccorso G; Pittoni G; Feltracco P; Ori C; Pagnan A; Cella G
Clin Appl Thromb Hemost; 2009 Dec; 15(6):628-35. PubMed ID: 19605376
[TBL] [Abstract][Full Text] [Related]
16. A Comparison of Efficacy Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Hereditary FVIII Deficiency With Inhibitor.
Faranoush M; Abolghasemi H; Mahboudi F; Toogeh G; Karimi M; Eshghi P; Managhchi M; Hoorfar H; Dehdezi BK; Mehrvar A; Khoeiny B; Vaziri B; Kamyar K; Heshmat R; Baghaeipour MR; Mirbehbahani NB; Fayazfar R; Ahmadinejad M; Naderi M
Clin Appl Thromb Hemost; 2016 Mar; 22(2):184-90. PubMed ID: 25343955
[TBL] [Abstract][Full Text] [Related]
17. [Recombinant factor VIIa (NovoSeven). A review of current and possible future indications].
Heuer L; Blumenberg D
Anaesthesist; 2002 May; 51(5):388-99. PubMed ID: 12125311
[TBL] [Abstract][Full Text] [Related]
18. Recombinant-activated coagulation factor VIIa (NovoSeven): current development.
Weiskopf RB
Vox Sang; 2007 May; 92(4):281-8. PubMed ID: 17456151
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VII and IX inhibitors.
Barthels M
Thromb Res; 1999 Aug; 95(4 Suppl 1):S31-8. PubMed ID: 10499907
[TBL] [Abstract][Full Text] [Related]
20. Recombinant activated factor VII in patients with acute liver failure with UNOS Status 1A: a single tertiary academic centre experience.
Pham HP; Hsu SX; Parker-Jones S; Samstein B; Diuguid D; Schwartz J
Vox Sang; 2014 Jan; 106(1):75-82. PubMed ID: 23815226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
